SCHEMBL853588

SCHEMBL853588

CC(C)(C)OC(=O)NCCOc1c(-c2cccc(Cl)c2)[nH]c(=O)c2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.41
CNR2 P34972 1/20 0.41
IDO1 P14902 3/20 0.40
KDM4E B2RXH2 2/20 0.40
CYP1A1 P04798 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2B6 P20813 1/20 0.40
CYP2C19 P33261 1/20 0.40
CYP3A43 Q9HB55 1/20 0.40
PARP1 P09874 2/20 0.38
PARP2 Q9UGN5 2/20 0.38
PDK2 Q15119 1/20 0.38
SCN9A Q15858 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL854686 0.90 PARP1 (0.51) CYP1A1CYP2D6CYP2B6CYP2C19CYP3A43
SCHEMBL853060 0.88 SERPINE1 (0.53) BCHECNR2CYP1A1CYP2D6CYP2B6
SCHEMBL15467756 0.86 CYP1A1 (0.46) BCHECNR2IDO1CYP1A1CYP2D6
SCHEMBL15467774 0.83 BCHE (0.46) BCHECNR2IDO1CYP1A1CYP2D6
SCHEMBL854015 0.82 BCHE (0.40) BCHECNR2IDO1KDM4ECYP1A1
SCHEMBL853576 0.81 PARP1 (0.55) CYP1A1CYP2D6CYP2B6CYP2C19CYP3A43
SCHEMBL854644 0.80 L3MBTL1 (0.43) BCHECNR2IDO1CYP1A1CYP2D6
SCHEMBL16227584 0.80 PARP1 (0.63) CYP1A1CYP2D6CYP2B6CYP2C19CYP3A43
SCHEMBL15467547 0.79 PARP1 (0.51) PARP1PARP2SERPINE1
SCHEMBL16227249 0.79 PARP1 (0.67) PARP1PARP2SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993594-B2 Isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-03-31 US disclosed
US-20140045846-A1 ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-02-13 US disclosed
EP-2432765-A1 ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2012-03-28 EP disclosed
WO-2010133647-A1 ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045846-A1 ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS PARP1, PARP2, PARP11 BCHE 4058/4885CNR2 603/4885IDO1 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.